Surrey Heartlands

Joint Formulary & PAD

Empagliflozin - Heart failure

You are here : Home > Formulary Search > Empagliflozin - Heart failure

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines BNF SPC
NICE
Restrictions / Comments :

Documentation

Guidelines (Local)
Heart Failure Treatment Pathway - Surrey Heartlands Feb 2024
Evidence Review
Empagliflozin for Heart Failure - NICE briefing paper - July 2022
Patient resource
Getting the most from your SGLT2 inhibitor (gliflozin) medicine - Patient information - Feb 25
Webpage
NICE TA773 - Empagliflozin for treating chronic heart failure with reduced ejection fraction (March 2022)
Webpage
NICE TA929 - Empagliflozin for treating chronic heart failure with preserved or moderately reduced ejection fraction - Nov 23
Information
Empagliflozin and dapagliflozin for heart failure with reduced ejection fraction - BLUE information sheet - Nov 2022.pdf

PAD Profile

ChemicalSubstance :
Empagliflozin
Indication :
Heart failure
Group Name :
Keywords :
SGLT2s, SGLT2 inhibitors, sodium glucose co-transporter 2 inhibitors, chronic heart failure, CHF, HFrEF, reduced ejection fraction
Brand Names Include :
Jardiance
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Heart failure
Supporting Documents :
6

Other Indications

Below are listed other indications that Empagliflozin is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Heart failure.

Committee Recommendations (3)

10 Feb 25 - Surrey Heartlands Medicines Safety Committee (MSC)

The Medicines safety Committee has approved the 'Getting the most from your SGLT2 inhibitor (‘gliflozin’) medicine' PIL which can be adapted for use by services.

07 Feb 24 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) approves empagliflozin:

  • as an option for treating adult chronic heart failure with reduced ejection fraction in addition to standard care (NICE TA773)
  • as an option for treating adult chronic heart failure with preserved or mildly reduced ejection fraction in addition to standard care (NICE TA929)

Treatment should be initiated or recommended by a heart failure specialist in patients with a formal diagnosis of heart failure as per NICE guideline on Chronic Heart Failure in adults

Heart Failure specialist defined as:

 • Cardiology consultant, specialist, or registrar

 • Heart failure specialist nurse

 • GP with a specialist interest in heart failure or GP cardiologist

 • General physician with heart failure expertise

 • Renal physician

02 Nov 22 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed a BLUE information sheet for empagliflozin and dapagliflozin for Adult Heart Failure with reduced ejection fraction (HFrEF) and a place in therapy document for these treatments in patients with Heart Failure.